Burning rock received fda breakthrough device designation for its overc™ multi-cancer detection blood test

Irvine, calif., jan. 03, 2023 (globe newswire) -- burning rock (nasdaq/lse: bnr), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today announced that its overc™ multi-cancer detection blood test (mcdbt) has been granted breakthrough device designation by the us food and drug administration (fda), which is the third of its kind globally.
BNR Ratings Summary
BNR Quant Ranking